Categories AlphaGraphs, Earnings, Finance, LATEST
BNY Mellon tops Q3 earnings estimates; misses on revenues
The Bank of New York Mellon Corporation (BK) topped market estimates on earnings for the third quarter of 2018 but missed out on revenue.
Total revenues grew 1% year-over-year to $4.07 billion, driven by higher fee and net interest revenues. Higher equity market values, growth in collateral management and clearance volumes as well as higher performance fees drove the 1% increase in fee revenues, while net interest revenues rose 6%, benefiting from higher interest rates.
Net income applicable to common shareholders grew 9% to $1.07 billion while EPS grew 13% to $1.06 from the prior-year period.
Non-interest expense rose 3%, primarily reflecting investments in technology and higher litigation expense, partly offset by decreases in staff and distribution and servicing expenses.
Total revenues in the Investment Services division rose 3% year-over-year, driven by increases across all the business lines. The revenue growth was fueled by various factors including higher net interest revenues, equity market values and transaction volumes.
Total revenues in the Investment Management division grew 2% on a year-over-year basis, helped by growth in the Asset Management and Wealth Management businesses.
Blackstone thrives on equity growth; Q3 results beat estimates
During the quarter, BNY Mellon returned $895 million to shareholders. Assets under management increased slightly to $1.8 trillion, driven mainly by higher market values and partially offset by the divestiture of CenterSquare Investment Management and negative impacts from the stronger US dollar.
BNY Mellon’s shares were down 2.7% as of 11:45 am ET. The stock has dropped 11% so far this year.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
Comments
Comments are closed.